Lotronex Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Lotronex (alosetron hydrochloride) is used to treat severe, chronic irritable bowel syndrome (IBS) in women who have had diarrhea as the main symptom for at least 6 months, and should be used only in women who have tried other IBS treatments without success. It has not been shown to be effective in men with IBS. It blocks the action of a chemical called serotonin in the intestines, slowing the movement of stools (bowel movements) through the intestines. Common side effects include headache, stomach upset, or hemorrhoids.
To lower the risk of constipation, Lotronex should be started at a dosage of 0.5 mg twice a day. If, after 4 weeks, the dosage is well tolerated but does not adequately control IBS symptoms, then it may be increased to up to 1 mg twice a day. Lotronex may interact with fluvoxamine, cimetidine, ketoconazole, itraconazole, voriconazole, isoniazid, hydralazine, procainamide, clarithromycin, telithromycin, HIV medicines, nelfinavir, or antibiotics. Tell your doctor all medications and supplements you use. Lotronex should be used only when prescribed during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Lotronex (alosetron hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Lotronex in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop taking alosetron and call your doctor at once if you have a serious side effect such as:
- new or worsening stomach pain;
- bleeding from your rectum or blood in your stools; or
- fast or uneven heartbeats.
Less serious side effects may include:
- mild stomach discomfort, bloating, or nausea;
- mild constipation;
- burping with heartburn;
- rectal hemorrhoids;
- bloating or gas;
- headache; or
- skin rash.
Read the entire detailed patient monograph for Lotronex (Alosetron Hydrochloride)
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Lotronex Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor immediately if you have any of these unlikely but serious side effects: bloating, depression.
Stop taking this medication and seek immediate medical attention if any of these unlikely but serious side effects occur: constipation, bloody stools, unexplained fever, unusually fast pulse, new or sudden worsening of stomach/abdominal/bowel pain.
A serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include: rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Lotronex (Alosetron Hydrochloride)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Lotronex FDA Prescribing Information: Side Effects
Table 1 summarizes adverse events from 22 repeat-dose studies in patients with IBS who were treated with 1 mg of LOTRONEX (alosetron hydrochloride) twice daily for 8 to 24 weeks. The adverse events in Table 1 were reported in 1% or more of patients who received LOTRONEX (alosetron hydrochloride) and occurred more frequently on LOTRONEX (alosetron hydrochloride) than on placebo. A statistically significant difference was observed for constipation in patients treated with LOTRONEX (alosetron hydrochloride) compared to placebo (p < 0.0001).
Table 1. Adverse Events Reported in ≥ 1% of IBS Patients
and More Frequently on LOTRONEX (alosetron hydrochloride) 1 mg B.I.D. Than Placebo
|LOTRONEX (alosetron hydrochloride)
1 mg B.I.D.
(n = 8,328)
(n = 2,363)
|Abdominal discomfort and pain||7%||4%|
|Gastrointestinal discomfort and pain||5%||3%|
|Regurgitation and reflux||2%||2%|
Gastrointestinal: Constipation is a frequent and dose-related side effect of treatment with LOTRONEX (see WARNINGS). In clinical studies constipation was reported in approximately 29% of IBS patients treated with LOTRONEX (alosetron hydrochloride) 1 mg twice daily (n = 9,316). This effect was statistically significant compared to placebo (p < 0.0001). Eleven percent (11%) of patients treated with LOTRONEX (alosetron hydrochloride) 1 mg twice daily withdrew from the studies due to constipation. Although the number of IBS patients treated with LOTRONEX (alosetron hydrochloride) 0.5 mg twice daily is relatively small (n = 243), only 11% of those patients reported constipation and 4% withdrew from clinical studies due to constipation. Among the patients treated with LOTRONEX (alosetron hydrochloride) 1 mg twice daily who. reported constipation, 75% reported a single episode and most reports of constipation (70%) occurred during the first month of treatment with the median time to first report of constipation onset of 8 days. Occurrences of constipation in clinical trials were generally mild to moderate in intensity, transient in nature, and resolved either spontaneously with continued treatment or with an interruption of treatment. However, serious complications of constipation have been reported in clinical studies and in postmarketing experience (see BOXED WARNING and WARNINGS). In Studies 1 and 2, 9% of patients treated with LOTRONEX (alosetron hydrochloride) reported constipation and 4 consecutive days with no bowel movement (see Clinical Trials). Following interruption of treatment, 78% of the affected patients resumed bowel movements within a 2-day period and were able to re-initiate treatment with LOTRONEX (alosetron hydrochloride) .
Hepatic: A similar incidence in elevation of ALT ( > 2-fold) was seen in patients receiving LOTRONEX (alosetron hydrochloride) or placebo (1.0% vs. 1.2%). A single case of hepatitis (elevated ALT, AST, alkaline phosphatase, and bilirubin) without jaundice was reported in a 12-week study. A causal association with LOTRONEX (alosetron hydrochloride) has not been established.
Long-Term Safety: Patient experience in controlled clinical trials is insufficient to estimate the incidence of ischemic colitis in patients taking LOTRONEX (alosetron hydrochloride) for longer than 6 months.
Other Events Observed During Clinical Evaluation of LOTRONEX (alosetron hydrochloride) : During its assessment in clinical trials, multiple and single doses of LOTRONEX (alosetron hydrochloride) were administered resulting in 11,874 subject-exposures in 86 completed clinical studies. The conditions, dosages, and duration of exposure to LOTRONEX (alosetron hydrochloride) varied between trials, and the studies included healthy male and female volunteers as well as male and female patients with IBS and other indications.
In the listing that follows, reported adverse events were classified using a standardized coding dictionary. Only those events that an investigator believed were possibly related to alosetron, occurred in at least 2 patients, and occurred at a greater frequency during treatment with LOTRONEX (alosetron hydrochloride) than during placebo administration are presented. Serious adverse events occurring in at least 1 patient for whom an investigator believed there was reasonable possibility that the event was related to alosetron treatment and occurring at a greater frequency in LOTRONEX (alosetron hydrochloride) than placebo-treated patients are also presented.
In the following listing, events are categorized by body system. Within each body system, events are presented in descending order of frequency. The following definitions are used: Infrequent adverse events are those occurring on one or more occasion in 1/100 to 1/1,000 patients; Rare adverse events are those occurring on one or more occasion in fewer than 1/1,000 patients.
Although the events reported occurred during treatment with LOTRONEX (alosetron hydrochloride) , they were not necessarily caused by it.
Cardiovascular: Infrequent: Tachyarrhythmias. Rare: Arrhythmias, increased blood pressure, and extrasystoles.
Drug Interaction, Overdose, and Trauma: Rare: Contusions and hematomas.
Eye: Rare: Light sensitivity of eyes.
Gastrointestinal: Infrequent: Hyposalivation, dyspeptic symptoms, gastrointestinal spasms, ischemic colitis (see WARNINGS), and gastrointestinal lesions. Rare: Abnormal tenderness, colitis, gastrointestinal signs and symptoms, proctitis, diverticulitis, positive fecal occult blood, hyperacidity, decreased gastrointestinal motility and ileus, gastrointestinal obstructions, oral symptoms, gastrointestinal intussusception, gastritis, gastroduodenitis, gastroenteritis, and ulcerative colitis.
Hepatobiliary Tract and Pancreas: Rare: Abnormal bilirubin levels and cholecystitis.
Lower Respiratory: Infrequent: Breathing disorders. Rare: Viral respiratory infections.
Neurological: Infrequent: Hypnagogic effects. Rare: Memory effects, tremors, dreams, cognitive function disorders, disturbances of sense of taste, disorders of equilibrium, confusion, sedation, and hypoesthesia.
Non-Site Specific: Infrequent: Malaise and fatigue, cramps, pain, temperature regulation disturbances. Rare: General signs and symptoms, non-specific conditions, burning sensations, hot and cold sensations, cold sensations, and fungal infections.
Psychiatry: Infrequent: Anxiety. Rare: Depressive moods.
Reproduction: Rare: Sexual function disorders, female reproductive tract bleeding and hemorrhage, reproductive infections, and fungal reproductive infections.
Skin: Infrequent: Sweating and urticaria. Rare: Hair loss and alopecia; acne and folliculitis; disorders of sweat and sebum; allergic skin reaction; eczema; skin infections; dermatitis and dermatosis; and nail disorders.
Postmarketing Experience: The following events have been identified during use of LOTRONEX (alosetron hydrochloride) in clinical practice. Because they were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to LOTRONEX (alosetron hydrochloride) .
Drug Abuse And Dependence
LOTRONEX (alosetron hydrochloride) has no known potential for abuse or dependence.
Read the entire FDA prescribing information for Lotronex (Alosetron Hydrochloride)
Additional Lotronex Information
Lotronex - User Reviews
Lotronex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get the latest treatment options.